Project Details
| Status | Active |
|---|---|
| Effective start/end date | 6/09/24 → 5/09/26 |
Keywords
- Clinical Trials
- EFC17600
Clinical Trial Phase
- Phase III (a & b)
A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 52-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis
- Kern, Johannes (Primary Chief Investigator (PCI))
- Fernandez-Peñas, Pablo (Chief Investigator (CI))
Project: Research